NR3C1 and inflammatory bowel disease: To our knowledge, there have been no treatments to date that have increased lymphocyte GCR expression, although there has been a report of successful pitavastatin treatment of acute lung injury in septic mice with associated increase in GCR in alveolar macrophages [28] and in studies using selective GCR agonists in the treatment of inflammatory bowel disease [29].